Bennicas Associates Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Bennicas Associates reduced its stake in AbbVie Inc by 3.04% during the most recent quarter end. The investment management company now holds a total of 19,110 shares of AbbVie Inc which is valued at $1,211,765 after selling 600 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.AbbVie Inc makes up approximately 1.07% of Bennicas Associates’s portfolio.

Other Hedge Funds, Including , Eagle Asset Management Inc sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 36,703 shares of ABBV which is valued $2,327,337. Simplex Trading sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 9,340 shares of ABBV which is valued $592,249.Davenport Co boosted its stake in ABBV in the latest quarter, The investment management firm added 7,433 additional shares and now holds a total of 103,773 shares of AbbVie Inc which is valued at $6,721,377. AbbVie Inc makes up approx 0.10% of Davenport Co’s portfolio.Edge Wealth Management reduced its stake in ABBV by selling 19,710 shares or 12.25% in the most recent quarter. The Hedge Fund company now holds 141,232 shares of ABBV which is valued at $9,061,445. AbbVie Inc makes up approx 3.72% of Edge Wealth Management’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in ABBV by selling 411,443 shares or 33.52% in the most recent quarter. The Hedge Fund company now holds 815,847 shares of ABBV which is valued at $52,344,744. AbbVie Inc makes up approx 0.23% of Bnp Paribas Arbitrage Sa’s portfolio.

AbbVie Inc opened for trading at $63.57 and hit $63.9 on the upside on Wednesday, eventually ending the session at $63.41, with a gain of 0.14% or 0.09 points. The heightened volatility saw the trading volume jump to 75,02,821 shares. Company has a market cap of $102,557 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.